Offers a non-surgical treatment option for tricuspid regurgitation, a commonly underdiagnosed heart valve disorder linked to heart failure
The Pharmaceuticals portfolio and pipeline are more promising than perhaps ever before
The company’s ACC lineup underscores a growing body of evidence backing the drug’s performance beyond controlled trials
TriClip offers a remarkably safe, minimally invasive treatment option for patients in need of tricuspid valve repair but who are unable to withstand surgery
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
